MT

Mayank Tenguria

Active Director Director DIN 09633797
DIN 09633797 First appointment Jun 2022 Primary industry Life Sciences
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2022
Shareholding value •••• Premium profile

About Mayank Tenguria

Data last updated:

Mayank Tenguria is a Director at Molmet Biotech Research Private Limited (since 2022). The company operates in Life Sciences. Molmet Biotech Research Private Limited reported revenue of ₹7.6 Lakh (FY 2024).

DIN 09633797
Primary Designation Director
Industry Life Sciences
First Appointment 10 Jun 2022
Oldest Company Age 4 yrs
Largest company Molmet Biotech Research Private Limited · ₹7.6 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Jun 20222022₹7.6 Lakh (FY 2024)Active

Board colleagues of Mayank Tenguria

Directorship timeline

Open interactive timeline →
Molmet Biotech Research Private Limited
Premium access

Shareholding and investment profile for Mayank Tenguria

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mayank Tenguria

Mayank Tenguria currently holds 1 directorship: Molmet Biotech Research Private Limited (Director, since 10 Jun 2022, revenue ₹7.6 Lakh (FY 2024)).

Mayank Tenguria was first appointed on 10 Jun 2022 as Director at Molmet Biotech Research Private Limited.

The current boards of Mayank Tenguria's companies include Dharmendra Singh Khichi (Molmet Biotech Research Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available